Patients with nodal MZL who progress within 24 months of initial systemic chemoimmunotherapy should be considered for targeted therapy. Approved targeted therapies for this subtype of MZL include Bruton tyrosine kinase (BTK) inhibitors (such as ibrutinib and zanubrutinib), phosphatidylinositol 3-kinase (PI3K) inhibitors (such as idelalisib, duvelisib, copanlisib, and umbralisib), and lenalidomide in combination with rituximab. There are limited data regarding the use of autologous stem cell transplantation in nodal MZL; this treatment is not commonly used due to potential for considerable toxicity and the availability of targeted therapies.
Learn more about treatment for nodal MZL.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Christina Poh. Fast Five Quiz: Relapsed/Refractory Marginal Zone Lymphoma - Medscape - Nov 03, 2021.